Ischemic Stroke Pipeline Landscape Analysis: 50+ Key Players & 50+ Pipeline Drugs

DelveInsight's, "Ischemic Stroke Pipeline Insight, 2022," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Ischemic Stroke Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Ischemic Stroke Pipeline Report
• DelveInsight's Ischemic Stroke Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
• The leading Ischemic Stroke Companies are working such as Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, Teijin Pharma Limited, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Ltd., GrandPharma (China) Co., Ltd., Suzhou Yabao Pharmaceutical R&D Co., Ltd., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Guangzhou Recomgen Biotech Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Genentech, Inc., Ever Supreme Bio Technology Co., Ltd., NoNO Inc., Pharming Technologies B.V., Biogen, Acticor Biotech, Avilex Pharma, SanBio, ZZ Biotech, Shin Poong Pharmaceutical, Prolong Pharmaceuticals, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, and others
• Promising Ischemic Stroke Pipeline therapies such as Vericiguat (BAY1021189), Isosorbide mononitrate (ISMN), Nitroglycerin, Prasugrel Loading Dose, Ticagrelor Maintenance Dose, clopidogrel, Rivaroxaban, mipomersen sodium, MEDI6012, and others.
• In the coming years, the Ischemic Stroke market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The Ischemic Stroke pipeline companies and academics that are working to assess challenges and seek opportunities that could influence Ischemic Stroke R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Recent Developmental Activities in the Ischemic Stroke Pipeline Report
• The company is developing MultiStem®, a proprietary stem cell product, for the treatment of diseases and conditions in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other indications. Factors expressed by MultiStem have the potential to deliver a therapeutic benefit in several ways, such as reducing inflammation, protecting damaged or injured tissue, and enhancing the formation of new blood vessels in regions of ischemic injury. These cells exhibit a drug-like profile in that they act primarily through the production of multiple factors that regulate the immune system, protect damaged or injured cells, promote tissue repair and healing, and the cells are subsequently cleared from the body over time. Currently, it is in Phase III stage of clinical trial evaluation to treat Ischemic Stroke.
• RNS60, is being developed to treat chronic neurodegenerative diseases driven by mitochondrial dysfunction, such as amyotrophic lateral sclerosis (ALS), and to improve recovery from neurological trauma, such as ischemic stroke. RNS60 uniquely activates intracellular signaling pathways that have anti-inflammatory effects and promote mitochondrial biogenesis, cell survival, and differentiation. In addition to protecting neurons and oligodendrocytes in the central nervous system, RNS60 modulates the activity of immune cells to restore cellular homeostasis throughout the body - without the undesirable side effects common to so many of today's medicines.
• Elezanumab (ABT 555) is a fully humanised monoclonal antibody, inhibiting repulsive guidance molecule a (RGMa), being developed by AbbVie, for the treatment of spinal cord injuries and acute ischemic stroke. Currently, it is in Phase II stage of clinical trial evaluation to treat acute ischemic stroke.
• LT3001, a novel molecule designed to restore occluded blood flow without causing hemorrhage, holds promise as a superior and safer therapy to expand the treatable population and improved the outcome after acute ischemic stroke.

Request a sample and discover the recent advances in Ischemic Stroke Treatment
Landscape @ https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ischemic Stroke Overview

Ischemic strokes occur when blood supply is cut off to part of the brain. This type of stroke accounts for the majority of all strokes. The blocked blood flow in an ischemic stroke may be caused by a blood clot or by atherosclerosis, a disease which causes narrowing of the arteries over time. Ischemic strokes can be caused by a blockage anywhere along the arteries feeding the brain. Immediate emergency treatment is critical to surviving a stroke with the least amount of damage to the brain and ability to function. Ischemic strokes occur when blood supply is cut off to part of the brain by a blood clot or narrowing of the arteries. Blood clots may be caused by an irregular heartbeat such as arrhythmia, problems with the heart valve, infection of the heart muscle, hardening of the arteries, blood-clotting disorders, inflammation of the blood vessels, or a heart attack. A less common cause of ischemic stroke occurs when blood pressure becomes too low (hypotension), reducing blood flow to the brain. This usually occurs with narrowed or diseased arteries. Low blood pressure can result from a heart attack, large loss of blood or severe infection. Each of these conditions affects the flow of blood through the heart and blood vessels and increases the risk of stroke. Strokes can happen to a person of any age, including children. However, the older a person is, the higher their risk of stroke. Strokes are more common in men, but more women die from them. A family history of stroke, or a personal history of stroke or heart attack, also increase the risk of stroke. Research also has shown African-Americans are at higher risk of stroke than Caucasians. People who have symptoms of a stroke need emergency medical care. Immediate medical attention may prevent life-threatening complications, more widespread brain damage, and is critical for the recovery.

Ischemic Stroke Emerging Drugs
• MultiStem: Athersys, Inc.
• Elezanumab: Tarveda Therapeutics
• LT3001: Lumosa Therapeutics
• RNS60: Revalesio Corporation

Ischemic Stroke Pipeline Therapeutic Analysis

There are approx. 50+ key companies which are developing the therapies for Ischemic Stroke. The companies which have their Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include Athersys, Inc.

Learn more about the emerging Ischemic Stroke Clinical Trials @ https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

DelveInsight's report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Scope of the Ischemic Stroke Pipeline Report
• Coverage- Global
• Ischemic Stroke Assessment by Product Type
• Ischemic Stroke Assessment by Stage and Product Type
• Ischemic Stroke Assessment by Route of Administration
• Ischemic Stroke Assessment by Stage and Route of Administration
• Ischemic Stroke Assessment by Molecule Type
• Ischemic Stroke Assessment by Stage and Molecule Type
• Ischemic Stroke Companies- Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, Teijin Pharma Limited, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Ltd., GrandPharma (China) Co., Ltd., Suzhou Yabao Pharmaceutical R&D Co., Ltd., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Guangzhou Recomgen Biotech Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Genentech, Inc., Ever Supreme Bio Technology Co., Ltd., NoNO Inc., Pharming Technologies B.V., Biogen, Acticor Biotech, Avilex Pharma, SanBio, ZZ Biotech, Shin Poong Pharmaceutical, Prolong Pharmaceuticals, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, and others.
• Ischemic Stroke Pipeline therapies- Vericiguat (BAY1021189), Isosorbide mononitrate (ISMN), Nitroglycerin, Prasugrel Loading Dose, Ticagrelor Maintenance Dose, clopidogrel, Rivaroxaban, mipomersen sodium, MEDI6012, and others.

Table of Content
1. Introduction
2. Executive Summary
3. Ischemic Stroke: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ischemic Stroke - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. MultiStem: Athersys, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Elezanumab: Tarveda Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. AVLX-144: Avilex Pharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. AP-188: Algernon Pharmaceutical
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ischemic Stroke Key Companies
21. Ischemic Stroke Key Products
22. Ischemic Stroke- Unmet Needs
23. Ischemic Stroke- Market Drivers and Barriers
24. Ischemic Stroke- Future Perspectives and Conclusion
25. Ischemic Stroke Analyst Views
26. Ischemic Stroke Key Companies
27. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Ischemic Stroke drugs?
• How many Ischemic Stroke drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ischemic Stroke?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ischemic Stroke therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ischemic Stroke and their status?
• What are the key designations that have been granted to the emerging drugs?

Got Queries? Get in touch with our Business Development Executive @ https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.